|
|
Chronic Hepatitis
|
|
Chronic Hepatitis
Idenix, Novartis seek approval for chronic hepatitis B treatment Jan 4, 2006
...and Novartis Pharmaceuticals Corp. said they have applied to the Food and Drug Administration for approval of a treatment for chronic hepatitis B. ...
- Boston Globe,
High Level of Hepatitis B Virus in Patients with Chronic Hepatitis ... Jan 4, 2006
TAIPEI, TAIWAN, and PRINCETON, NJ -- January 4, 2006 -- Chronic hepatitis B patients with high levels of circulating hepatitis B virus (HBV) appear to be at ...
- DG News
High Level of Hepatitis B Virus in Patients With Chronic HBV ... Jan 4, 2006
TAIPEI, Taiwan, and PRINCETON, NJ -- Chronic hepatitis B patients with high levels of circulating hepatitis B virus (HBV) appear to be at increased risk of ...
- EndoNurse,
Not all hepatitis is contagious Jan 25, 2006
...of hepatitis. There are other forms of persistent chronic hepatitis that are never contagious through any means. Autoimmune, alcoholic ...
- Northwest Herald,
Chronic Hepatitis C Treatment, Peg-Intron(R) And Rebetol(R) ... Dec 27, 2005
...for PEG-INTRON(R) (peginterferon alfa-2b) Powder for Injection in combination with REBETOL(R) (ribavirin) Capsules -- the treatment of chronic hepatitis C in ...
- Medical News Today (press release),
Tenofovir works as well for HBV in coinfected with 3TC resistance ... Jan 27, 2006
First-line combination therapy of chronic hepatitis B with tenofovir plus lamivudine versus sequential therapy with tenofovir monotherapy after lamivudine ...
- Aidsmap,
'Meth mouth' takes bite out of jail's health care resources Jan 28, 2006
...the components of meth. People in jail in their mid-20s already are having chronic hepatitis. Also, sexually transmitted diseases ...
- Amarillo.com (subscription),
Migenix: infectious ambitions in hepatitis Jan 25, 2006
...fierce. Chronic hepatitis C virus (HCV) infection is currently managed through pegylated interferon and ribavirin combination therapy. ...
- Pharmaceutical Business Review
Fertility center pushes adult vaccination services Jan 22, 2006
If the Hepatitis B virus remains in the blood for more than six months, the patient becomes afflicted with chronic hepatitis B and may have to spend the rest ...
- Sun.Star,
ALT levels may not give true picture of liver disease in HIV/HCV ... Jan 26, 2006
...by persistently normal ALT levels, which are too often considered a sign of well-balanced liver status in HIV-positive subjects with chronic hepatitis C virus ...
- Aidsmap,
My dad was dying and we never knew Jan 26, 2006
But Dr Helen Harris, the HPA's hepatitis C expert, said: “Most individuals with chronic hepatitis C can be successfully treated, but the success of treatment ...
- Norfolk Eastern Daily Press,
Schering-Plough Initiates PEG-INTRON(R) Maintenance Study in ... Jan 13, 2006
HIV patients, or about 10 million people worldwide, are coinfected with the hepatitis C virus (HCV) and HIV.(1) Liver disease caused by chronic hepatitis C is ...
- PR Newswire (press release),
Asian-American volunteers trying to help underserved Jan 22, 2006
The liver infection can progress to chronic hepatitis B, a lifetime condition that can lead to cirrhosis, liver cancer and liver failure. ...
- Arizona Republic,
Idenix and Novartis Announce New Drug Application Submitted to the ... Jan 3, 2006
United States Food and Drug Administration (FDA) seeking marketing approval for the 600 mg dose of telbivudine for the treatment of chronic hepatitis B. This ...
- Finanzen.net,
MIGENIX to Initiate MX-3253 HCV Viral Kinetics Study in Treatment ... Jan 23, 2006
The Company's clinical programs include drug candidates for the treatment of chronic hepatitis C infections (Phase II), the prevention of catheter-related ...
- PharmaLive.com (press release),
Romark to Develop Alinia (nitazoxanide) as New Treatment for ... Jan 10, 2006
PRNewswire/ -- Romark Laboratories announced that it is initiating US clinical development of Alinia(R) (nitazoxanide) tablets for treating chronic hepatitis C ...
- PharmaLive.com (press release),
Tarvacin(TM) Anti-Viral Hepatitis C Clinical Program in ... Jan 18, 2006
...diseases and cancer, today announced that it has accelerated its clinical program for Tarvacin(TM) Anti-Viral for the treatment of chronic hepatitis C virus ...
- RxPG NEWS,
Tripep initiates clinical development of ChronVac-C® for the ... Jan 16, 2006
Inovio™ (AMEX:INO; www.inovio.com) regarding clinical development of Tripep's therapeutic vaccine ChronVac-C® for the treatment of chronic hepatitis C virus ...
- Biotech Intelligence (press release),
Study Reported in JAMA Concludes That High Level of Hepatitis B ... Jan 3, 2006
3 /PRNewswire/ -- Chronic hepatitis B patients with high levels of circulating hepatitis B virus (HBV) appear to be at increased risk of developing liver ...
- PR Newswire (press release),
Study Reported in JAMA Concludes That High Level of Hepatitis B ... Jan 3, 2006
TAIPEI, Taiwan and PRINCETON, NJ, January 03, 2006 /PRNewswire/ -- Chronic hepatitis B patients with high levels of circulating hepatitis B virus (HBV) appear ...
- PharmaLive.com (press release),
E. Coli Defense Mechanism May Provide Key to Disrupting Bacteria ... Jan 16, 2006
...to 6 months. Most people that contract Hepatitis A fully recover and it does not lead to chronic Hepatitis. Unfortunately, about ...
- Newsinferno.com,
Letter Warns of Hepatitis B Reactivation Associated with Anti-TNF ... Jan 18, 2006
Hepatitis B virus (HBV) reactivation has been reported very rarely in patients with chronic hepatitis B infection receiving the anti-TNF alpha agents Enbrel ...
- DG News
Risk of Hepatocellular Carcinoma Linked with Serum Levels of ... Jan 9, 2006
Among patients with chronic hepatitis B infection, risk of developing hepatocellular carcinoma (liver cancer) increases with increasing serum levels of ...
- Cancer Consultants (press release),
Idenix Pharmaceuticals Reports Positive 4-Week Data From A Phase ... Jan 9, 2006
...combined with pegylated interferon has the potential to substantially improve treatment efficacy compared to current therapy for chronic hepatitis C patients ...
- PR Newswire (press release),
Hepatitis C treatment difficult in older patients Jan 18, 2006
Iwasaki's group analyzed outcomes among 208 patients with chronic hepatitis C. The treatment involved injections of interferon daily for 2 weeks then three ...
- Reuters.uk,
Viral Hepatitis Conference to Take Place February 27-28, 2006 in ... Jan 5, 2006
5, 2006 /PRNewswire/ -- Chronic hepatitis C (HCV) and B (HBV) are the most common causes of chronic viral hepatitis in the United States, posing serious risks ...
- PharmaLive.com (press release),
Non-invasive probe can stage liver disease in HIV / hepatitis C co ... Jan 22, 2006
...“Liver stiffness measurement is a promising non-invasive method for the assessment of fibrosis in HIV-infected patients with chronic hepatitis C virus ...
- Aidsmap,
Hepatitis C Vaccine Jan 15, 2006
...against the disease. Research shows the function of dendritic cells is altered in patients with chronic hepatitis C. Sylvia van ...
- Ivanhoe,
Inovio Biomedical to Develop Vaccine for Hepatitis C in ... Jan 17, 2006
ChronVac(R) vaccine and Inovio's Medpulser(TM) DNA Delivery System may become a completely new form of therapy for the treatment of chronic hepatitis C virus ...
- Genetic Engineering News,
Fatigue may be misdiagnosed as depression during anti-HCV therapy ... Jan 23, 2006
Kraus MR et al. Psychiatric symptoms in patients with chronic hepatitis C receiving interferon alfa-2b therapy. J Clin Psychiatry 64 (6), 708 - 714, 2003.
- Aidsmap,
Suspect Vanishes from Kabardino-Balkaria Jail Jan 27, 2006
Tekaeva says her son has a heart murmur, a stomach ulcer, and chronic hepatitis and bronchitis, as well as a bullet in his hip dating from his time in ...
- Institute for War and Peace Reporting,
Schering-Plough to evaluate Peg-Intron in combined disease Jan 16, 2006
Liver disease caused by chronic hepatitis C is now a leading cause of morbidity and mortality among HIV-infected patients in the developed world. ...
- Pharmaceutical Business Review
Design and conduct of clinical trials in Africa Jan 23, 2006
...in Africa. Muriel is currently the principal investigator of a trial for treatment of chronic hepatitis B in Senegal. She serves ...
- African News Dimension,
Difficulty in treating older hepatitis C patients with combination ... Jan 5, 2006
...hepatology. Chronic hepatitis C virus (HCV), the most common cause of liver disease, affects approximately 300 million people worldwide. ...
- EurekAlert (press release),
Migenix to start HCV drug trial in Q2 Jan 23, 2006
...said it would begin a Phase 2b viral kinetics clinical trial of its first-in-class oral therapy MX-3253 (celgosivir) in patients with chronic hepatitis C virus ...
- United Press International
Human Genome Sciences Reports on Progress Toward Commercialization ... Jan 10, 2006
Toward Commercialization - - Plan to Advance LymphoStat-B(TM) to Phase 3 in SLE - - Plan to Advance Albuferon(TM) to Phase 3 in Chronic Hepatitis C - - Working ...
- PR Newswire (press release),
Peregrine accelerates Tarvacin development Jan 19, 2006
...biopharm company Peregrine Pharmaceuticals has accelerated its clinical program for Tarvacin, an anti-viral designed to treat chronic hepatitis C, expecting to ...
- Pharmaceutical Business Review
Reaching the Asian-American community Jan 21, 2006
Chuang serves on a hepatitis B task forceThe liver infection can progress to chronic hepatitis B, a lifetime condition that can lead to cirrhosis, liver cancer ...
- Arizona Republic,
Romark Laboratories to Develop Alinia as New Treatment for Chronic ... Jan 10, 2006
TAMPA, Fla. -- Romark Laboratories announced that it is initiating US clinical development of Alinia (nitazoxanide) tablets for treating chronic hepatitis C. ...
- EndoNurse,
Older HCV Patients Have Tough Time with Combination Therapy Jan 9, 2006
9 - Older Japanese patients with chronic hepatitis C (HCV) infections are less likely than younger patients to tolerate combination therapy with Intron A ...
- MedPage Today,
Telbivudine Continues to Show Superior Efficacy over Lamivudine in ... Dec 29, 2005
HAWAII -- December 29, 2005 -- The investigational polymerase inhibitor telbivudine continues to show strong antiviral activity in chronic hepatitis B (HBV ...
- DG News
Interferon with Ribavirin is safe and effective for children with ... Jan 1, 2006
Nearly half of 118 children with chronic Hepatitis C virus ( HCV ) treated with a combination of Interferon-alpha-2b ( Intron A ) and an optimized dose of ...
- Xagena.it,
Human Genome Sciences Reports on Progress Toward Commercialization ... Jan 10, 2006
...the interim results of a Phase 2 trial of Albuferon (albumin-interferon alpha) in combination with ribavirin (RBV) in patients with chronic hepatitis C who ...
- MSN Money
ViRexx Founders Receive BioAlberta Lifetime Achievement Award Jan 19, 2006
ViRexx Medical Corp. (TSX:VIR)(AMEX:REX), a company focused on immunotherapy treatments for certain cancers, chronic hepatitis B & C and embolotherapy ...
- Genetic Engineering News,
Researchers Develop New Vaccine Candidate Against Hepatitis C Jan 10, 2006
For those who develop chronic hepatitis, the immune system cannot clear the infection. "In patients with chronic hepatitis C, there ...
- Science Daily (press release)
Peregrine accelerates Tarvacin HCV study Jan 18, 2006
The company said it has enrolled patients several months ahead of schedule in an early stage clinical trial using Tarvacin for chronic hepatitis C virus ...
- BusinessWeek
First filing for Novartis' hep B drug Jan 4, 2006
...submission of telbivudine, which has been tipped as a big seller after clinical data suggested it was more effective in tackling chronic hepatitis B than ...
- Pharma Times (subscription),
Data Comparing Viread(R) and Emtriva(R) to Combivir(R) as Part of ... Jan 18, 2006
Truvada, Emtriva and Viread are not indicated for the treatment of chronic hepatitis B virus (HBV) infection and the safety and efficacy of these drugs has not ...
- Genetic Engineering News,
BioAlberta honours its own Jan 21, 2006
...stage ovarian cancer. The company is also developing drugs for treating liver cancer and chronic hepatitis. Tyrrell, a renowned ...
- Edmonton Journal,
HIV/HCV coinfected patients have poorer immunologic response to ... Jan 17, 2006
...that the “blunted immune response in HIV/hepatitis C coinfected patients may be due the nonspecific immune stimulation driven by chronic hepatitis C virus ...
- Aidsmap,
Increase ribavirin dose for better HCV treatment response in ... Jan 18, 2006
Fried MW et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 347(13): 975-982, 2002.
- Aidsmap,
Inovio and Tripep to develop hepatitis C vaccine Jan 17, 2006
Tripep's ChronVac vaccine and Inovio's medpulser DNA delivery system may become a completely new form of therapy for the treatment of chronic hepatitis C virus ...
- Pharmaceutical Business Review
First-Time Generic Approvals: Copegus, Tegretol, Roxicodone Jan 24, 2006
Ribavirin tablets are indicated for use with peginterferon alfa-2a in the treatment of adults with chronic hepatitis C virus (HCV) infection who have ...
- Medscape (subscription)
Supporting the liver Jan 21, 2006
Both nutrients provide nutritional support in the management of a damaged liver, fatty liver, chronic hepatitis and alcohol-induced liver damage. ...
- Malaysia Star,
ViRexx Founders Receive BioAlberta Lifetime Achievement Award Jan 19, 2006
...(TSX:VIR)(AMEX:REX), a company focused on immunotherapy treatments for certain cancers, chronic hepatitis B & C and embolotherapy treatments for tumors, today ...
- PharmaLive.com (press release),
Organ Donor Rates for 2005 Worst Ever. Jan 10, 2006
...is expected to double over the next decade, requiring more donors due the expected doubling of end stage liver disease from chronic hepatitis C. (Currently ...
- Scoop.co.nz (press release),
Keryx Biopharmaceuticals, Inc. Announces Appointment of Senior ... Jan 4, 2006
A(R) (recombinant interferon-alpha 2-b), for the treatment of malignant melanoma, hairy cell leukemia, AIDS-related Kaposi's sarcoma, chronic hepatitis C and ...
- PR Newswire (press release),
Data Comparing Viread(R) and Emtriva(R) to Combivir(R) as Part of ... Jan 18, 2006
Truvada, Emtrivaand Viread are not indicated for the treatment of chronic hepatitis Bvirus (HBV) infection and the safety and efficacy of these drugs hasnot ...
- Finanzen.net,
Idenix Submits Hep B Application Jan 3, 2006
The drug, called telbivudine, is designed to be taken orally once a day for chronic hepatitis B. While most people who become infected with the liver-damaging ...
- MSN Money
(PZ) Novartis Delivers Strong Performance with Record Results in ... Jan 18, 2006
Results from the GLOBE study, a Phase III trial in patients with chronic hepatitis B, presented in November 2005 showed that treatment of patients after one ...
- Houston Chronicle,
Anadys Pharmaceuticals to Present at the 24th Annual JP Morgan ... Jan 5, 2006
Completion of 501, 502 and 503 clinical studies of ANA975 in healthy volunteers * Upcoming 28-day study of ANA975 in patients with chronic hepatitis C virus ...
- PR Newswire (press release),
Cambridge firm seeks FDA approval Jan 3, 2006
...said they have applied to the US Food and Drug Administration for approval of a new treatment for chronic hepatitis B based on results from an ongoing clinical ...
- Boston Globe,
Hepatitis C Patients Taxing Medical System Dec 30, 2005
About 3 million people in the United States have chronic hepatitis C virus (HCV), and many of them contracted it in the 1970s, before testing and safe needle ...
- Forbes
New Test Detects Cirrhosis Early Jan 12, 2006
...cirrhosis of the liver. The test could then be used to follow people with chronic hepatitis C viral infection. Often, 10 years can ...
- About - News & Issues,
XTL Biopharmaceuticals Announces Appointment of Ron Bentsur as ... Jan 2, 2006
...a combination of two monoclonal antibodies against the hepatitis C virus - presently in Phase 1 clinical trials in patients with chronic hepatitis C. XTLbio's ...
- PR Newswire (press release),
Valeant buys InterMune hepatitis C drug Jan 3, 2006
...company said. Infergen is used to treat adult patients suffering from chronic hepatitis C viral infections with liver disease. Costa ...
- San Francisco Business Times,
Adefovir Dipivoxil Produces Sustained Improvement in HBV over Long ... Dec 29, 2005
KOHALA COAST, HAWAII -- December 29, 2005 -- Patients with chronic hepatitis B (HBV) who continue taking adefovir dipivoxil (ADV) for up to 5 years continue to ...
- DG News
Anadys Pharmaceuticals Appoints Frank V. Chisari, MD, to Its ... Jan 10, 2006
...of viral clearance and persistence during HBV infection, and established the scientific basis for development of specific immunotherapy for chronic hepatitis. ...
- PharmaLive.com (press release),
Idenix, Novartis submit NDA to FDA for HepB drug Jan 4, 2006
...the submission of an application to the US Food and Drug Administration (FDA) seeking approval for telbivudine, a new treatment for chronic hepatitis B. ...
- New Ratings
GlobeImmune Secures Additional $4.1 Million and Closes Series B ... Jan 10, 2006
...in patients with pancreatic cancer as well as complete a placebo-controlled Phase 1b clinical trial of GI-5005 in patients with chronic hepatitis C infection. ...
- PR Newswire (press release),
(PRN) - ACM Income Fund, Inc. Monthly Distribution ... [+] Jan 3, 2006
...[+]. (PRN) - Study Reported in JAMA Concludes That High Level of Hepatitis B Virus in Patients With Chronic Hepatitis B Infection Predicts Increased Risk For ...
- Bolsamania.com,
Biochemical connection between hepatitis C virus and liver cancer ... Jan 6, 2006
Approximately 200 million people worldwide suffer from chronic hepatitis C, which can persist in the body for decades after an initial infection, often causing ...
- Xagena.it,
FDA Approvals: RPS Adeno Detector, Elecsys NT-proBNP Test, TBA ... Jan 6, 2006
...for TBA quantification include the diagnosis of liver conditions in which TBA levels are elevated, such as acute and chronic hepatitis, liver sclerosis, and ...
- Medscape (subscription)
Bid to remove biopsy barrier to hep C treatment Jan 10, 2006
This meant the decision about whether to treat a patient “will come back to anyone with established chronic hepatitis C infection, which will be determined ...
- AustralianDoctor.com (subscription),
AVI BioPharma's NEUGENE Shows Success Against Deadly Ebola Virus ... Jan 13, 2006
...only how effective this approach can be, but it is also encouraging for our work in treating additional viral diseases, such as chronic hepatitis C infection ...
- PharmaLive.com (press release),
Valeant Pharmaceuticals Completes Acquisition of Hep-C Drug ... Jan 3, 2006
It is currentlyindicated as monotherapy for the treatment of adult patients sufferingfrom chronic hepatitis C viral infections with compensated liverdisease ...
- Finanzen.net,
Valeant Pharmaceuticals Completes Acquisition of Hep-C Drug ... Jan 3, 2006
It is currently indicated as monotherapy for the treatment of adult patients suffering from chronic hepatitis C viral infections with compensated liver disease ...
- Business Wire (press release),
Zacks.com Announces That Vivian Lewis Highlights the Following ... Jan 17, 2006
...began of the AB-rated generic equivalent of Roche's Copegus (R), used in combination with peginterferon alfa-2a to treat adults with chronic hepatitis C virus. ...
- Business Wire (press release),
HGS Signs Amgen, PDL For Partners In Non-Core Assets Jan 10, 2006
Also, the company expects to start Phase III development of Albuferon (albumin-interferon alpha 2b) for chronic hepatitis C by the end of 2006, assuming ...
- BioWorld Online (subscription),
InterMune Completes Divestiture of Infergen(R) for up to $135.5 ... Jan 3, 2006
...completion of the sale of its United States and Canadian rights to Infergen(R) (interferon alfacon-1), approved for the treatment of chronic hepatitis C virus ...
- PR Newswire (press release),
NEWS RELEASE Jan 3, 2006
States Food and Drug Administration (FDA) seeking marketing approval for the 600 mg dose of telbivudine for the treatment of chronic hepatitis BUS BioDefense ...
- Financial News USA (press release),
(PRN) - CYIOS Corporation Announces Record Quarterly and Annual ... Jan 10, 2006
Awards ... [+. PRN) - Romark to Develop Alinia(R) (nitazoxanide) as New Treatment for Chronic Hepatitis C ... [+. PRN) - Spartan ...
- Bolsamania.com,
Switching from twice-daily Combivir to once-daily Truvada in ... 23 Nov 2005
Truvada is not indicated for the treatment of chronic hepatitis B virus ( HBV ) infection and its safety and efficacy has not been established in patients co ...
- Xagena.it,
MIGENIX Initiates Enrollment in Phase IIb Hepatitis C Clinical ... Nov 22, 2005
Celgosivir is an orally administered, first-in-class alpha glucosidase 1 inhibitor, in development for the treatment of chronic hepatitis C virus (HCV ...
- PR Newswire (press release),
Bristol's BARACLUDE Tablet for Chronic Hepatitis B Virus Infection ... Nov 11, 2005
...of Health, Labor and Welfare has granted the company with a priority review status for BARACLUDE Tablet, an agent for treating chronic hepatitis B virus (HBV ...
- Japan Corporate News (press release),
Human Genome Sciences Reports Interim Results of Phase 2 Clinical ... Nov 15, 2005
...the safety, tolerability and efficacy of Albuferon(TM) (albumin-interferon alpha) in combination with ribavirin (RBV) in patients with chronic hepatitis C who ...
- PR Newswire (press release),
XTLbio Announces Data Demonstrating the Antiviral Activity of One ... Nov 16, 2005
...in reducing viral levels." The dual antibody product - XTL-6865 - is presently in Phase Ia clinical trial in patients with chronic hepatitis C. Results from ...
- PR Newswire (press release),
Peregrine Pharmaceuticals Names Leading Viral Experts to Its ... Nov 16, 2005
Tarvacin Anti- Viral is in a Phase I clinical trial for the treatment of chronic hepatitis C infection (HCV) and is being studied preclinically for use in the ...
- PharmaLive.com (press release),
Ask a doc Nov 18, 2005
...death. Hepatitis A is always acute, while hepatitis B & C may become chronic. Hepatitis D needs hepatitis B to coexist. Hepatitis ...
- Central Florida Future (subscription),
GLOBE Study Demonstrates Telbivudine Provides Significantly ... Nov 14, 2005
...on all evaluated virologic markers compared to lamivudine after one year, in both HBeAg-positive and HBeAg-negative patients with chronic hepatitis B. Idenix ...
- PR Newswire (press release),
Largest Hepatitis C Trial in US Patients Shows Weight-Based ... Nov 14, 2005
Chronic hepatitis C can cause cirrhosis, liver failure and liver cancer. It has been estimated that at least 20 percent of patients ...
- PR Newswire (press release),
Pharmasset Announces Five Clevudine Presentations at AASLD Nov 11, 2005
...under which Pharmasset will develop and commercialize Clevudine, also known as L-FMAU, for the treatment of chronic hepatitis B virus (HBV) infections in the ...
- PharmaLive.com (press release),
Zoek in het archief Nov 14, 2005
...( BW)(CA-GILEAD-SCIENCES)(GILD) Five-Year Data Evaluating Long-Term Therapy with Hepsera for Hepatitis B ''e'' Antigen-Negative Chronic Hepatitis B Presented ...
- Netherlands Corporate News,
GLOBE study finds telbivudine superior to current standard of care ... Nov 13, 2005
Basel, November 14, 2005 - Results from the GLOBE study, a Phase III trial in patients with chronic hepatitis B, showed that treatment of patients after one ...
- Biotech Intelligence (press release),
Globe Study Demonstrates Telbivudine Provides Significantly ... Nov 14, 2005
...response on all evaluated virologic markers compared to lamivudine after one year, in both HBeAg-positive and HBeAg-negative patients with chronic hepatitis B. ...
- DG News
Children with chronic Hepatitis C benefit from interferon with ... Nov 5, 2005
Nearly half of 118 children with chronic Hepatitis C virus (HCV) treated with a combination of interferon-alpha-2b and an optimized dose of ribavirin achieved ...
- Medical News Today (press release),
Five-Year Data Evaluating Long-Term Therapy with Hepsera(R) for ... Nov 14, 2005
R) (adefovir dipivoxil) for up to five years of treatment among patients with hepatitis B "e" antigen-negative, presumed precore mutant chronic hepatitis B. In ...
- Genetic Engineering News,
Boehringer Ingelheim Announces 48-Week Results from Aptivus(R) ... Nov 21, 2005
...have occurred. * Patients with chronic hepatitis B or C co-infection have an increased chance of developing liver problems. These ...
- Yahoo! News (press release)
Oxxon Therapeutics Reports Positive Preliminary Phase IIa Data ... Nov 11, 2005
...from a Phase IIa, 52-week study of its novel therapeutic vaccine comprising a PrimeBoost immunotherapeutic approach in patients with chronic hepatitis B. The ...
- Business Wire (press release),
ViroPharma Announces That Treatment With HCV-796 Reduces Hepatitis ... Nov 10, 2005
NYSE:WYE). In this trial, HCV-796 demonstrated antiviral effects in adult patients with chronic hepatitis C infection. The patient ...
- PrimeZone (press release),
New Studies with Pegasys(R) plus Copegus(R) in Hepatitis C ... Nov 11, 2005
15, from 8:00 am - 12:30 pm "Economic evaluation of standard-therapy (ST) for chronic hepatitis C (CHC) with Peginterferon alfa-2a (40KD) (PegIFN 2a) plus ...
- PR Newswire (press release),
Human Genome Sciences Completes Patient Enrollment in a Phase 2b ... Oct 25, 2005
...dosing in a Phase 2b clinical trial of Albuferon(TM) (albumin-interferon alpha) in combination with ribavirin in patients with chronic hepatitis C virus (HCV ...
- PR Newswire (press release),
Dear Doctor: Hepatitis causes, treatments vary Nov 8, 2005
No specific medications or shots are necessary. The treatment for chronic hepatitis is more complicated and is specific for each problem. ...
- Pittsburgh Post Gazette,
Baraclude (Entecavir) Two-year Data Analysis Did Not Detect ... Nov 14, 2005
...for the Study of Liver Diseases (AASLD) demonstrated no virologic rebounds due to resistance through 2 years in nucleoside-naive chronic hepatitis B adult ...
- DG News
AASLD: Peg-Interferon and Ifn-Ribavirin Combo Keep HCV in Check ... Nov 16, 2005
But how durable those response rates were has been uncertain. "The durability of an SVR after interferon-based treatment for chronic hepatitis C is an ...
- MedPage Today,
Long-Term Adefovir Dipivoxil Effective for HIV and Treatment ... Nov 21, 2005
...[Presentation title: Long-Term Experience of Adefovir Dipivoxil Add-on Therapy in Chronic Hepatitis B Patients Co-infected with HIV and Lamivudine-Resistant HBV ...
- DG News
Short Therapy Regimens Effective for Hepatitis C Virus Genotype 2 ... Nov 21, 2005
...concluded. [Presentation title: Short-Term Treatment Duration for HCV-2 and HCV-3 Infected Patients with Chronic Hepatitis. Abstract 849].
- DG News
More Hepatitis B Education Needed in Asian-American Communities Nov 11, 2005
PARK, NC -- One in three Asian-Americans surveyed in a recent poll reported they had lost a family member due to complications of chronic hepatitis B. However ...
- EndoNurse,
Hepatitis Combination Therapy Okay for Children: Study Nov 15, 2005
...that interferon alfa-2b in combination with oral ribavirin is effective and reasonably safe for the treatment of childhood chronic hepatitis C. Sustained ...
- Hepatitis Neighborhood,
Data on Schering-Plough's Oral HCV Protease Inhibitor to be ... Nov 7, 2005
SCH 503034 capsules, both as monotherapy and in combination therapy with PEG-INTRON(R) (peginterferon alfa-2b), in patients with chronic hepatitis C genotype 1 ...
- PR Newswire (press release),
Emergent BioSolutions Starts Clinical Study of Single Dose Oral ... Nov 21, 2005
The company is also using this system to develop a therapeutic vaccine to treat chronic Hepatitis-B. The company believes that this technology could prove ...
- PR Newswire (press release),
AASLD: Hepatitis B Yields More to Telbivudine than Epivir Nov 15, 2005
15 - In patients with chronic hepatitis B infection, investigational telbivudine (LdT), a newer nucleoside analog, showed significantly better antiviral ...
- MedPage Today,
Pegasys(R) Shows Encouraging Interim Results for Hepatitis C ... Nov 11, 2005
...alpha interferon, and Copegus were approved by the FDA in December 2002 for use in combination for the treatment of adults with chronic hepatitis C who have ...
- PR Newswire (press release),
Actilon(TM), Coley Pharmaceutical Group's Drug Candidate for ... Nov 14, 2005
These may be positive signs of Actilon's ability to promote both an immediate as well as long-term control of chronic Hepatitis C. Clinical results to date ...
- Yahoo! News (press release)
New Studies with Pegasys(R) plus Copegus(R) in Hepatitis C ... Nov 11, 2005
Pegasys, a pegylated alpha interferon, and Copegus are indicated for use in combination for the treatment of adults with chronic hepatitis C who have ...
- PR Newswire (press release),
Intarcia Therapeutics Announces Interim Results From a Phase 2 ... Nov 15, 2005
The current standard of care for treating chronic hepatitis C is combination therapy consisting of pegylated interferon and ribavirin. ...
- PR Newswire (press release),
Data on Schering-Plough's Oral HCV Protease Inhibitor to be ... Nov 6, 2005
SCH 503034 capsules, both as monotherapy and in combination therapy with PEGINTRON(R) (peginterferon alfa-2b), in patients with chronic hepatitis C genotype 1 ...
- PR Newswire UK (press release),
Schering-Plough's Oral HCV Protease Inhibitor Demonstrates Potent ... Nov 14, 2005
Chronic hepatitis C affects more than 10 million people in major world markets and is the leading cause of chronic liver disease. ...
- PR Newswire (press release),
ANA975 Phase I Clinical Data to Be Presented at the American ... Nov 14, 2005
..."These data are encouraging and support further clinical studies of ANA975 as an investigational agent for oral therapy of chronic hepatitis C virus," said ...
- Yahoo! News (press release)
PEG-INTRON(R) and REBETOL(R) Combination Therapy Demonstrates ... Nov 12, 2005
12 /PRNewswire-FirstCall/ -- Patients with chronic hepatitis C treated with PEG-INTRON® (peginterferon alfa-2b) and REBETOL® (ribavirin, USP) combination ...
- Yahoo! News (press release)
AASLD: Weight-Based Dosing of Rebetol Improves Outlook for HCV Nov 17, 2005
17 - Giving Rebetol (ribavirin) based on the weight of a chronic hepatitis C (HCV) patient, rather than a flat dose, resulted in better viral control and fewer ...
- MedPage Today,
ViRexx Announces Postive Interim Results for Occlusin'TM' 50 ... Nov 16, 2005
ViRexx Medical Corp. (TSX:VIR) a company focused on immunotherapy treatments for certain cancers, chronic hepatitis B & C and embolotherapy treatments for ...
- Genetic Engineering News,
ViRexx Announces Postive Interim Results for Occlusin 50 Injection Nov 16, 2005
...(TSX:VIR) a company focused on immunotherapy treatments for certain cancers, chronic hepatitis B & C and embolotherapy treatments for tumors, today announced ...
- PharmaLive.com (press release),
New drug gives patients hope Nov 17, 2005
...leading researcher on the study, said research indicated telbivudine had the potential to reduce serious complications associated with chronic hepatitis B and ...
- China Daily,
InterMune Announces Clinical Data Presented at AASLD That Support ... Nov 14, 2005
Consensus Interferon and Ribavirin in Patients with Chronic Hepatitis C who were Non-responders to Prior Therapy with either Interferon Alfa and Ribavirin or ...
- PR Newswire (press release),
Preliminary 24-Week Data Evaluating the Impact of Switching from ... Nov 17, 2005
Truvada is not indicated for the treatment of chronic hepatitis B virus (HBV) infection and its safety and efficacy has not been established in patients co ...
- PharmaLive.com (press release),
AASLD Issues Call for Americans to Fight Liver Disease as ... Nov 11, 2005
Lack of awareness of Hepatitis B is leading to unnecessary complications and death for the 1.25 million individuals with chronic Hepatitis B in the United ...
- PR Newswire (press release),
Metabasis Comments on Positive Data Reported at AASLD Late-Breaker ... Nov 15, 2005
QD. The safety and efficacy of pradefovir is being studied for the treatment of compensated chronic hepatitis B (HBV). Pradefovir ...
- PR Newswire (press release),
The Great Cholesterol Myth Nov 18, 2005
Many Chinese peasant farmers have chronic hepatitis, which creates low cholesterol levels, and also leads to liver failure and liver cancer. ...
- Spiked,
MultiVu Video Feed: Important Health News for Asian Americans ... Nov 10, 2005
This lack of awareness can lead to complications and death for the 1.25 million people with chronic hepatitis B in the United States. ...
- PR Newswire (press release),
AASLD Presentations Support the Initiation of a Broad Phase II ... Nov 11, 2005
...presented at the conference are from a dose-ranging Phase Ib study of VX-950 dosed in an oral suspension for 14 days in patients with chronic hepatitis C. Dr ...
- PR Newswire (press release),
Protease inhibitor fights hepatitis C Nov 16, 2005
...for the Study of Liver Diseases on new protease inhibitors is extremely exciting and ushers in a new era for patients with chronic hepatitis C," said Bruce ...
- myDNA.com,
Hepatitis C Often Untreated and Outcomes Lag behind Trials in ... Nov 9, 2005
...several databases of selected sites within the Kaiser Permanente Northern California Health System, and identified 1470 patients with chronic hepatitis C who ...
- DG News
XTLbio presents encouraging data on Hepatitis C drug candidate Nov 16, 2005
The dual antibody product -- XTL-6865 -- is presently in Phase Ia clinical trial in patients with chronic hepatitis C. Results from this trial are expected in ...
- Globes,
PEG-INTRON(R) and REBETOL(R) Combination Therapy Demonstrates ... Nov 12, 2005
Patients with chronic hepatitis C treated with PEG-INTRON(R) (peginterferon alfa-2b) and REBETOL(R) (ribavirin, USP) combination therapy achieved consistently ...
- PR Newswire UK (press release),
Roche Announces Expansion of First Major Study to Examine Efficacy ... Nov 3, 2005
Previous studies with pegylated interferon combination therapy for chronic hepatitis C have shown that African Americans are less likely to respond to ...
- PR Newswire (press release),
Biolex Therapeutics announces initiation of study of Hepatitis C ... Nov 2, 2005
...with the drug delivery and development company OctoPlus (Leiden, the Netherlands), initially for the treatment of patients with chronic hepatitis C. Locteron ...
- Carolina Newswire (press release),
Preliminary 24-Week Data Evaluating the Impact of Switching from ... Nov 17, 2005
Truvada is notindicated for the treatment of chronic hepatitis B virus (HBV)infection and its safety and efficacy has not been established inpatients co ...
- Finanzen.net,
Interferon with Ribavirin Safe and Effective for Children with ... Nov 1, 2005
HOBOKEN, NJ -- November 1, 2005 -- Nearly half of 118 children with chronic Hepatitis C virus (HCV) treated with a combination of interferon-alpha-2b and an ...
- DG News
Novartis says telbivudine hepatits B drug better than standard ... Nov 13, 2005
ZURICH (AFX) - Novartis AG said results from a phase III trial showed that its chronic hepatitis B once daily pill telbivudine is superior to GlaxoSmithKline ...
- Forbes
NYC Asian-Americans higher Hepatitis B Nov 11, 2005
This lack of awareness can lead to complications and death for the 1.25 million people with chronic hepatitis B in the United States, the AASLD said. ...
- United Press International
InterMune Announces Presentations at the 56th Annual Meeting of ... Nov 8, 2005
Viral Factors which Predicted Liver-Related Deaths and Development of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B About Infergen®. ...
- Yahoo! News (press release)
Hepatitis C Caring Ambassadors Program Hopeful That Proposed ... Nov 3, 2005
...occur each year. Chronic hepatitis C is a serious, life-threatening disease causing significant morbidity and mortality. HCV is ...
- Market Wire (press release)
High hepatitis rates spur state health campaign Oct 28, 2005
...higher risk: gay men, drug users, homeless, transplant patients, prisoners, pregnant women and people in close contact with those who have chronic hepatitis B. ...
- Atlanta Journal Constitution (subscription),
IDM Launches Phase II Trial in Europe of its Therapeutic Vaccine ... Nov 9, 2005
...development partnerships with SANOFI-AVENTIS in cancer immunotherapy, and with INNOGENETICS in vaccine development for the treatment of chronic hepatitis B and ...
- Biotech Intelligence (press release),
Novartis: hepatitis B pill better than standard drug Nov 14, 2005
...virus. Novartis said chronic hepatitis B is the tenth leading cause of death worldwide, with more than 350 million people infected. ...
- Reuters
(PRN) - EnCirca Announces the DestinationPort Service for .travel ... Nov 14, 2005
Antiviral Measures vs. Lamivudine in Patients With Chronic Hepatitis B, the 10th Leading Cause of Death Worldwide ... [+. PRN) - Prana ...
- Bolsamania.com,
Canadian Study on Hepatitis C Treatment Based on Patient Weight ... Nov 12, 2005
SGP), which holds a global monopoly on PEG-INTRON (peginterferon alfa-2b) and REBETOL (ribavirin, USP) used in the treatment of chronic hepatitis C, sponsored ...
- AXcess News,
OctoPlus Initiates Clinical Trials With Locteron(TM), a Controlled ... Nov 2, 2005
...is specifically designed by OctoPlus with the intention to address key unmet needs in the treatment of its primary indication, chronic hepatitis C infection. ...
- Yahoo! News (press release)
Novelos Therapeutics in Collaboration with Shriners Hospitals to ... Nov 8, 2005
NOV-205 is being developed to treat chronic hepatitis C in the US NOV-205 is designed to act as a hepatoprotective agent with immunomodulating and antiviral ...
- Business Wire (press release),
Biolex Therapeutics Successfully Completes Phase 1 Study for First ... Oct 26, 2005
...proprietary biodegradable PolyActive(TM) drug delivery technology, and is designed to be a best-in-class therapeutic for patients with chronic hepatitis C. ...
- Yahoo! News (press release)
Hepatitis B Education Needed in Asian-American Communities Oct 31, 2005
Park, NC (AHN) - One in three Asian-Americans surveyed in a recent poll report they had lost a family member due to complications of chronic hepatitis B. ...
- All Headline News
Romark Completes Clinical Study of Alinia in Treating Clostridium ... Nov 18, 2005
Alinia is under development in the United States for treatment of Clostridium difficile-associated diarrhea, Crohn's disease and chronic hepatitis C. About ...
- PR Newswire (press release),
HEPATITIS C PATIENTS FARE BETTER WITH PEGASYS(R) - STUDY FROM ... Nov 14, 2005
..."Randomized, Open Label Trial Comparing efficacy and safety of pegylated interferon alfa 2a vs 2b treatment of patients with chronic hepatitis infected with ...
- ITNews,
Early Results Show PEGASYS(R) Working Where Peg-Intron(R) has ... Nov 11, 2005
PEGASYS has also been approved in over 40 countries around the world for the treatment of chronic hepatitis B including the EU, Switzerland, Hong Kong, New ...
- PR Newswire UK (press release),
Veterans At Risk: Hepatitis C Still Serious Risk Nov 9, 2005
...“We have seen a dramatic increase in referrals of patient with liver cirrhosis and liver cancer, the most dangerous complications of chronic hepatitis C.�.
- Newswise (press release)
Cambridge biotech develops hepatitis C pill Nov 10, 2005
Many people with chronic hepatitis C don’t choose to get the current therapy because of horrible side effects that include flu symptoms, depression and ...
- Boston Herald,
Serono's Third Quarter 2005 Adjusted EPS Increased by 37.6% Oct 24, 2005
Genetics Institute (SGI) - Primary endpoint met in multicentre phase 3 study of interferon-beta-1a monotherapy for the treatment of chronic hepatitis C in ...
- PR Newswire (press release),
Schering-Plough Reports 2005 Third Quarter Financial Results Oct 24, 2005
...instructions allowing for a shorter, 24-week course of PEG-INTRON and REBETOL combination therapy among a subgroup of patients with chronic hepatitis C virus ...
- PR Newswire (press release),
ViRexx to Present at Technology Finance 2005 Nov 15, 2005
15, 2005) - ViRexx Medical Corp. (TSX:VIR) a company focused on immunotherapy treatments for certain cancers, chronic hepatitis B & C and embolotherapy ...
- CCNMatthews (press release),
Serono's Third Quarter 2005 Adjusted EPS Increased by 37.6% Oct 24, 2005
...to complete four Phase 3 and three Phase 2 clinical trials including today's positive outcome of the study of interferon-beta-1a in chronic hepatitis C in ...
- Yahoo! News (press release)
Human Genome Sciences Announces Financial Results for the Third ... Oct 25, 2005
...the enrollment and initial dosing of a Phase 2b trial of Albuferon in combination with ribavirin in treatment-naive patients with chronic hepatitis C. Our ...
- PR Newswire (press release),
Coley Pharmaceutical Group Reports Third Quarter Financial Results Nov 10, 2005
...is Actilon(TM), which completed a randomized, controlled Phase Ib four-week dose-escalation clinical trial as a monotherapy in chronic Hepatitis C virus, or HCV ...
- PharmaLive.com (press release),
ViRexx To Present At Rodman & Renshaw Techvest Seventh Annual ... Nov 3, 2005
...(TSX:VIR), a company focused on immunotherapy treatments for cancer, chronic hepatitis B & C and embolotherapy treatments for tumors today announced that Marc ...
- PharmaLive.com (press release),
ViRexx To Present At Rodman & Renshaw Techvest Seventh Annual ... Nov 3, 2005
3, 2005--ViRexx Medical Corp. (TSX:VIR), a company focused on immunotherapy treatments for cancer, chronic hepatitis B & C and embolotherapy treatments for ...
- Business Wire (press release),
victory over death Nov 8, 2005
...liver. The rest of the liver went to a 58-year-old woman from Beersheba, a mother of two children, suffering from chronic hepatitis. ...
- Times Online,
Peregrine studying Tarvacin to treat flu Oct 24, 2005
Tarvacin is currently in an early human trial for chronic hepatitis C, but Peregrine said it is also studying the drug in preclinical flu models. ...
- BusinessWeek
(PRN) - Nam Tai Electronics, Inc.: New Monthly Sales Record of $80 ... Nov 14, 2005
...[+]. (PRN) - BARACLUDE(TM) (entecavir) Two-year Data Analysis Did Not Detect Emergence of Resistance in Nucleoside-Naive Chronic Hepatitis B Patients ... [+. ...
- Bolsamania.com,
Anadys Pharmaceuticals Reports Third Quarter 2005 Financial ... Nov 1, 2005
...offering expenses. * Announced Publication of Clinical Study of Isatoribine in Chronic Hepatitis C Demonstrating Proof of Concept. The ...
- PR Newswire (press release),
Three Rivers Pharmaceuticals Announces FDA Tentative Approval of ... Oct 24, 2005
CRANBERRY TOWNSHIP, Pa., Oct. 24 /PRNewswire/ -- Three Rivers Pharmaceuticals, LLC today announced that the US Food and Drug Administration ...
- PR Newswire (press release),
Three Rivers Pharmaceuticals Announces FDA Tentative Approval of ... Oct 25, 2005
CRANBERRY TOWNSHIP, Pa., October 24, 2005 /PRNewswire/ -- Three Rivers Pharmaceuticals, LLC today announced that the US Food and Drug Administration (FDA) has ...
- PharmaLive.com (press release),
International Approvals: Aptivus, Noxafil, Xolair Oct 31, 2005
Extra vigilance is warranted in patients with chronic hepatitis B or hepatitis C coinfection because of the increased risk of hepatotoxicity. ...
- Medscape (subscription)
The Intrinsic Evil of Evolutionary Humanism Nov 10, 2005
There are 1 million cases of HIV, 31-50 million of herpes simplex, 24 million of HPV, and 1 million cases of chronic hepatitis B. ...
- MichNews.com,
Crystal Research Associates, LLC Issues Executive Informational ... Nov 9, 2005
...pipeline currently features a balanced portfolio, which contains several preclinical to Phase III product candidates to treat chronic Hepatitis C Virus (HCV ...
- Market Wire (press release)
MIGENIX to Present at the Rodman & Renshaw Techvest 7th Annual ... Nov 1, 2005
The Company's clinical programs include drug candidates for the treatment of chronic hepatitis C infections (Phase II), the prevention of catheter-related ...
- PR Newswire (press release),
Veridien Corporation Receives EPA Label Approval For Hepatitis A ... Oct 27, 2005
...year. As well, the CDC estimates that the number of Americans with chronic hepatitis infections exceeds 4.95 million people. (www ...
- Business Wire (press release),
Hep B and C are curable: Experts Oct 23, 2005
...for the two dreaded diseases — Hepatitis B and C. This was stated by Dr SK Sarin while speaking on the issue of management in chronic Hepatitis B and C at ...
- Times of India,
Association between Plasma Interleukin-18 Levels and Liver Injury ... Oct 29, 2005
1 Department of Medicine and Aging, and 2 Centre of Excellence on Aging, G. d’Annunzio University, School of Medicine, Chieti; 3 Unit of Hepatology, Santo ...
- Annals of Clinical & Laboratory Science,
- Presented by Faith & Values Media, “Naomi’s New Morning� ... Nov 14, 2005
They sold over 20 million albums and won five Grammy awards. In 1990, Naomi’s career was interrupted by chronic hepatitis. After ...
- Religion News Service,
MIGENIX Completes First Clinical Study of Celgosivir in Chronic ... Sep 27, 2005
...study of celgosivir (MX-3253), an orally administered, first-in-class, a-glucosidase I inhibitor, in development for the treatment of chronic hepatitis C virus ...
- Canada NewsWire (press release)
Chronic HCV Patients Not Getting Needed Hepatitis A Vaccine, Finds ... Sep 21, 2005
Bini and his group also found that despite the fairly significantly susceptibility to HAV, only 94 of the 1,193 patients with chronic hepatitis C infection had ...
- Hepatitis Neighborhood
Most chronic hepatitis C sufferers will develop cirrhosis in later ... Sep 4, 2005
Nearly 80 percent of chronic hepatitis C sufferers who have the disease for several decades will develop cirrhosis or end-stage liver disease later in life ...
- I-Newswire.com (press release)
Most chronic hepatitis C patients will develop cirrhosis in later ... Sep 2, 2005
Gastroenterological Association ( AGA ) journal Clinical Gastroenterology and Hepatology, showed that nearly 80 percent of chronic hepatitis C sufferers who ...
- Xagena.it
Combination Therapy Using Chronic Hepatitis-C Drug 'PEGASYS' Plus ... Sep 13, 2005
...[Head Office: Chuo-ku, Tokyo; President Osamu Nagayama (hereinafter, Chugai)] announced today that combination therapy using chronic hepatitis-C drug "PEGASYS ...
- PharmaLive.com (press release)
Combination Therapy Using Chugai Pharmaceutical's Chronic ... Sep 14, 2005
...by Chugai. PEGASYS is a pegylated interferon agent that treats chronic hepatitis C infection with a once-a-week dosage. The monotherapy ...
- PharmaLive.com (press release)
Dr. Lorne Tyrrell of ViRexx Wins Prestigious EnCana Principal ... Sep 30, 2005
30, 2005) - ViRexx Medical Corp. (TSX:VIR), a company focused on immunotherapy treatments for cancer, chronic hepatitis B & C and embolotherapy treatments for ...
- CCNMatthews (press release)
Doctors warn of hepatitis 'timebomb' Sep 29, 2005
Protection Agency, which is the national centre for surveillance of hepatitis C, has estimated 200,000 people in England may have chronic hepatitis C infection ...
- Telegraph.co.uk
Dr. Lorne Tyrrell of ViRexx Wins Prestigious EnCana Principal ... Sep 30, 2005
...(TSX:VIR), a company focused on immunotherapy treatments for cancer, chronic hepatitis B & C and embolotherapy treatments for tumors, announced that Dr. Lorne ...
- PharmaLive.com (press release)
EUROPEAN GOVERNMENTS WARNED: TAKE ACTION ON HEPATITIS C NOW OR ... Sep 29, 2005
It is therefore entirely unnecessary for so many hepatitis C patients to suffer the serious consequences associated with chronic hepatitis C when you consider ...
- ITNews
Novartis, new products portfolio Oct 1, 2005
...successfully reached its primary composite efficacy endpoint of therapeutic response in the Phase III GLOBE registration trial in chronic hepatitis B. ...
- Xagena.it
India to observe Hepatitis Awareness Day Oct 1 Sep 30, 2005
According to available data, in India alone, 10.9 million people have chronic hepatitis C. National trends indicate a sizeable concentration of hepatitis C ...
- NewKerala.com
Living with the sleeping dragon Sep 26, 2005
It's been estimated that 70,000 New Zealanders have chronic hepatitis B and a further 28,000 have chronic hepatitis C. Both types can be transmitted through ...
- Stuff.co.nz
Most Chronic Hepatitis C Sufferers Will Develop Cirrhosis In Later ... Sep 6, 2005
1, 2005) -- Nearly 80 percent of chronic hepatitis C sufferers who have the disease for several decades will develop cirrhosis or end-stage liver disease later ...
- Science Daily (press release)
Doctors not up to scratch on hepatitis Sep 28, 2005
...$2470). Chronic hepatitis B patients have to pay much more than those who have hepatitis A or C, which are far less prevalent. "Medical ...
- China Daily
One million hepatitis C patients could respond to therapy by 2014 Sep 30, 2005
30 Sep 2005, 13:06 GMT - In 2004 around 366,000 patients infected with chronic hepatitis C responded to pegylated interferon + ribavirin therapy. ...
- Pharmaceutical Business Review
Bioenvision's Phase II Trial of Virostat Very Active in Hepatitis ... Sep 28, 2005
...interim results from the ongoing investigator sponsored Phase II clinical study of BIVN-401 (Virostat) in adults with refractory, chronic Hepatitis C Virus ...
- Business Wire (press release)
Coley Pharmaceutical Group Initiates Second Phase Ib Clinical ... Sep 27, 2005
Phase Ib clinical study of Actilon(TM) (CPG 10101) alone and in combination with the current standard of care for the treatment of chronic Hepatitis C virus ...
- PR Newswire (press release)
Flamel Technologies Announces Positive Preliminary Results of a ... Sep 23, 2005
Phase I/II data from a trial demonstrating the safety, tolerability, and long-acting activity of IFN-alpha-XL in patients with chronic hepatitis C virus (HCV ...
- Business Wire (press release)
China's doctors not up to scratch on hepatitis B Sep 29, 2005
...prevented. China has an estimated 120 million chronic hepatitis B carriers, equivalent to the combined populations of France and Britain. ...
- TODAYonline
HEPATITIS C IS ON THE RISE Sep 29, 2005
A total of 250 patients received treatment for chronic hepatitis C, 100 from the former Soviet Union, 10 Albanians and the rest Greek. ...
- Macedonian Press Agency
Potent drug vs hepatitis B introduced Sep 2, 2005
DOCTORS now have an important new medication to treat chronic hepatitis B by suppressing viral replication and the risk of developing liver disease. ...
- INQ7 Interactive, Inc.
DATAMONITOR: 1 million Hep C patients could respond to therapy by ... Sep 28, 2005
NEW YORK, September 27, 2005- In 2004 around 366,000 patients infected with chronic hepatitis C (CHC) responded to pegylated interferon + ribavirin therapy ...
- PharmaLive.com (press release)
Seerat Aziz, MD , Peter W. Callen, MD , Flavio Vincenti, MD and ... Sep 29, 2005
A 57-year-old female patient received a liver transplant for end-stage liver disease secondary to chronic hepatitis C and alcohol abuse. ...
- Journal of Ultrasound in Medicine
Coley initiates trial of hepatitis C drug Sep 27, 2005
Inc. on Tuesday said it is starting an early-stage clinical trial of an experimental drug to treat chronic Hepatitis C virus. Coley ...
- ABC News
UPDATE 1-Coley initiates trial of hepatitis C drug Sep 27, 2005
...(COLY.O: Quote, Profile, Research) on Tuesday said it is starting an early-stage clinical trial of an experimental drug to treat chronic Hepatitis C virus. ...
- Reuters
Positive Clinical Results Allow IDM to Enter Second Stage of Phase ... Sep 27, 2005
...development partnerships with SANOFI-AVENTIS in cancer immunotherapy, and with INNOGENETICS in vaccine development for the treatment of chronic hepatitis B and ...
- Yahoo! News (press release)
MIGENIX to present at 2005 UBS Global Life Sciences Conference in ... Sep 29, 2005
The Company's clinical programs include drug candidates for the treatment of chronic hepatitis C infections (Phase II), the prevention of catheter-related ...
- PR Newswire (press release)
Cohen Independent Research Group Initiates Coverage on Novelos ... Sep 26, 2005
NOV-205 is being developed to treat chronic hepatitis C in the US NOV-205 is designed to act as a hepatoprotective agent with immunomodulating and antiviral ...
- Business Wire (press release)
September is Liver Cancer Awareness Month Sep 18, 2005
The most common cause of cirrhosis is chronic hepatitis B, a condition that afflicts about 10-12 percent of all Filipinos. Chronic ...
- Manila Bulletin
FLAMEL ANNOUNCES HEPATITIS C TRIAL RESULTS Sep 26, 2005
Phase I and II data from a trial demonstrating the safety, tolerability, and long-acting activity of IFN-alpha-XL in patients with chronic hepatitis C virus ...
- Small Times
CboH Launches Hepatitis B Vaccine Sep 23, 2005
...of the children that were infected with the Hepatitis B virus did not show any symptoms in their infancy but decades later the chronic Hepatitis disease, would ...
- AllAfrica.com
Unlikely men pass along yeast infections ASK DR. H MITCHELL HECHT Sep 20, 2005
...exist: 1) you have an acute active hepatitis B infection (doubtful since your tests were abnormal 10+ years ago); 2) you have chronic hepatitis B infection ...
- Wilkes Barre Times-Leader
Pharmasset Appoints Lynn B. Hill as Vice President, Alliance & ... Sep 27, 2005
We currently have four product candidates: Clevudine(tm), which is in late-stage clinical trials for the treatment of chronic Hepatitis B; Reverset(tm) and ...
- PharmaLive.com (press release)
Highlights of rising and falling US stocks Sep 27, 2005
Pharmaceutical Group (COLY) added 10% after the company said it was starting a clinical study of its Actilon drug for the treatment of chronic Hepatitis C. The ...
- Investor's Business Daily (subscription)
Most With Long-Term HCV Will Develop Cirrhosis, Doctors Maintain Sep 14, 2005
A group of British doctors predicts the vast majority of people with chronic hepatitis C will go on to develop the scar-forming condition of the liver known as ...
- Hepatitis Neighborhood
RioTech Pharmaceuticals Raises GBP 3/4 Million in Private ... Sep 12, 2005
The funds will drive the preclinical development of the Company's lead product, a novel interferon alpha-8 (IFN-alpha-8) chronic hepatitis C (CHC) therapy. ...
- Canada NewsWire (press release)
A New Player In The Battle Against Hepatitis Prevents Inflammation ... Sep 4, 2005
...persons. In some cases, the person remains a carrier of the virus, and chronic hepatitis and even cancer of the liver can develop. ...
- Science Daily (press release)
Researcher wins prestigious award Sep 21, 2005
An Edmonton researcher whose work led to a breakthrough in treating chronic hepatitis B has received an award worth $100,000. Dr ...
- Edmonton Journal
Pegylated Interferon- 2b and Lamivudine in Hepatitis Be Antigen ... Sep 6, 2005
Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet. ...
- Annals of Internal Medicine
Novartis Presents Positive Phase III Data on Key Compounds and ... Sep 19, 2005
...successfully reached its primary composite efficacy endpoint of therapeutic response in the Phase III GLOBE registration trial in chronic hepatitis B. Full one ...
- PrimeZone (press release)
Fatty Liver Not a Risk Factor for Cancer, Say Doctors Sep 14, 2005
George and his fellow researchers followed more than 450 people with chronic hepatitis C who had been treated in their liver unit over a 12-year period. ...
- Hepatitis Neighborhood
Parents urged to teach children backpack safety Sep 4, 2005
Few people with chronic hepatitis C virus are being routinely vaccinated against the hepatitis A virus, even though this type of immunization is strongly ...
- Indianapolis Star
RNAi Interferes With Disease Sep 9, 2005
Finding a mouse that, with the aid of drugs, can live with a chronic hepatitis B infection isn't all that unusual. But the mice ...
- Wired News
FDA tentatively approves Teva hepatitis treatment Sep 18, 2005
...of Roche's Copegus Tablets, a product indicated for use in combination with peginterferon alfa-2a for treatment of adults with chronic hepatitis C virus ...
- Globes
Alnylam and Isis License Intellectual Property for MicroRNA Gene ... Sep 13, 2005
No vaccine is currently available to prevent hepatitis C and treatment for chronic hepatitis C is too costly for most persons in developing countries to afford ...
- Genetic Engineering News
GlaxoSmithKline to increase supply of hepatitis paediatric ... Sep 23, 2005
...risk of long-term consequences from hepatitis B infection in the first years of life such as a high probability of developing chronic hepatitis and subsequent ...
- Medical News Today (press release)
Warning of a silent killer Sep 12, 2005
Americans make up less than 4 percent of the US population, they represent more than 55 percent of the 1.3 million Americans infected with chronic hepatitis B. ...
- OCRegister (subscription)
Roche says hepatitis C treatment gets Japanese priority review Sep 13, 2005
In Japan, Pegasys was approved in October 2003 with the indication for monotherapy treatment of chronic hepatitis C and is marketed under the tradename of ...
- MarketWatch
Prof. Dr. Ozkan Elected As Member Of Eaclpp Executive Board Sep 28, 2005
Meanwhile, our work on 'Psychiatric Situation and Living Standards of Patients with Chronic Hepatitis' was presented with the best research award of the year. ...
- Turkish Press
GlobeImmune Selects Nextrials' Prism to Manage Clinical Data in ... Sep 27, 2005
...products known as Tarmogens to treat cancer and infectious disease, is using Prism to manage a clinical study for treatment for chronic hepatitis C infection. ...
- Frontline Solutions
Low Hep A Vaccination in Hep C Patients Aug 30, 2005
30 (HealthDay News) -- Few people with chronic hepatitis C virus are being routinely vaccinated against the hepatitis A virus, even though this type of ...
- HealthCentral.com
GlobeImmune Selects Nextrials' Prism to Manage Clinical Data in ... Sep 19, 2005
...as Tarmogens(TM) to treat cancer and infectious disease, is currently using Prism to manage a clinical study for a treatment for chronic hepatitis C infection. ...
- PharmaLive.com (press release)
Flamel Interferon Lowers Side Effects Sep 23, 2005
In a clinical trial of 53 chronic hepatitis C patients, those given Flamel's IFN-alpha-XL appeared to have fewer adverse events than patients receiving ...
- Forbes
GlobeImmune Raises Over $34 Million in Series B Financing Sep 14, 2005
...company's first Phase 1 clinical trial in cancer with GI-4000 and file an IND on a second Tarmogen, GI-5005, for the treatment of chronic hepatitis C infection ...
- PR Newswire (press release)
Clean surroundings Sep 1, 2005
..."These chemical ingredients lead to longstanding and acute liver infection, liver cirrhosis, chronic hepatitis and even liver cancer," he added. ...
- Independent-Bangladesh
MIGENIX Reports First Quarter Fiscal 2006 Results Sep 7, 2005
MX-3253 (treatment of chronic Hepatitis C virus infections): Enrollment in the Phase IIa monotherapy study was completed, having achieved a total of 43 ...
- Yahoo! News (press release)
ViRexx completes $4 million private placement Sep 12, 2005
TSX Exchange "VIR" EDMONTON, Sept. 12 /CNW/ - ViRexx Medical Corp. (TSX: VIR) a company focused on immunotherapy treatments for cancer, chronic hepatitis B & C ...
- Canada NewsWire (press release)
ViRexx Completes $4 Million Private Placement Sep 12, 2005
12, 2005) - ViRexx Medical Corp. (TSX:VIR) a company focused on immunotherapy treatments for cancer, chronic hepatitis B & C and embolotherapy treatments for ...
- CCNMatthews (press release)
XTL biotech halves net losses as firm takes focused approach Sep 7, 2005
...disease after liver transplants. In the long run, XTL hopes the drugs can be used to treat chronic hepatitis. Two months ago Weiss ...
- Ha'aretz (subscription)
New Vaccine Included in Immunisation Programme Sep 2, 2005
He talked of the symptoms, which manifest later in life resulting in diseases such as cancer and chronic hepatitis, which leads to unavoidable deaths. ...
- AllAfrica.com
Hep C Sufferers at Greater Risk of Cirrhosis: Study Sep 2, 2005
Almost 80 percent of people who have chronic hepatitis C for several decades or more will wind up developing cirrhosis or end-stage liver disease, British ...
- HealthCentral.com
Most hepatitis C victims get cirrhosis Sep 1, 2005
LONDON, Sept. 1 (UPI) -- A British study finds that almost 80 percent of people with chronic hepatitis C will eventually develop cirrhosis. ...
- United Press International
Low HIV DNA levels and strong HIV-specific immune responses ... Sep 7, 2005
None had symptoms of HIV disease. Two patients were coinfected with chronic hepatitis B virus and seven individuals had chronic hepatitis C virus infection. ...
- Aidsmap
InterMune Announces Webcast of Corporate Presentation at the UBS ... Sep 21, 2005
In addition to three-times-a-week Infergen(R) (interferon alfacon-1), a currently marketed product indicated for the treatment of chronic hepatitis C virus (HCV ...
- PR Newswire (press release)
Teva Gets Tentative Generic Copegus OK Sep 16, 2005
Copegus is indicated for use in combination with peginterferon alfa-2a for treatment of adults with chronic hepatitis C virus infection who have compensated ...
- MSN Money
Quilt shows victims of hepatitis C's silent onslaught Sep 15, 2005
..."You wouldn't even know it. I thought I had the flu for four months, went to a doctor and he said, 'Oh, by the way, you have chronic hepatitis C.'. ...
- DetNews.com
Drug combo backed for high BP Sep 14, 2005
A new indication for peginterferon alfa-2a (Pegasys) for treatment of chronic hepatitis B in patients with evidence of viral replication and liver ...
- AustralianDoctor.com (subscription)
Hepatitis A Sep 12, 2005
Unlike hepatitis B and C, hepatitis A doesn't develop into chronic hepatitis or cirrhosis — both potentially fatal conditions. ...
- MayoClinic.com
ViRexx completes $4 million private placement Sep 12, 2005
EDMONTON, Sept. 12 - ViRexx Medical Corp. (TSX: VIR) a company focused on immunotherapy treatments for cancer, chronic hepatitis B & C and embolotherapy ...
- PharmaLive.com (press release)
Teva Announces Tentative Approval of Ribavirin Tablets Sep 16, 2005
...of Roche's Copegus(R) Tablets, a product indicated for use in combination with peginterferon alfa-2a for treatment of adults with chronic hepatitis C virus ...
- PharmaLive.com (press release)
GlobeImmune raises $34M Sep 14, 2005
1 clinical trials, is used to treat lung and gastrointestinal tract cancers, and GI-5005, in Phase 1b trials, is used to treat chronic hepatitis C infection.
- Denver Business Journal
Biotech gets $34 million Sep 14, 2005
GlobeImmune will use the money to conduct clinical trials to gauge the effectiveness of its drugs to treat pancreatic cancer and chronic hepatitis. ...
- Rocky Mountain News
*vwd/BUSINESS WIRE: Gilead reduziert Preise für "Viread" und " ... Aug 29, 2005
Viread, Emtriva and Truvada are not indicated for the treatment of chronic hepatitis B virus (HBV) infection and the safety and efficacy of these drugs has not ...
- Vereinigte Wirtschaftsdienste
Company Information Center Sep 1, 2005
...of royalties from sales of PEG-INTRON, which is marketed worldwide by Schering-Plough Corporation (NYSE: SGP) for the treatment of chronic hepatitis C. The ...
- Business Wire (press release)
Coffee Drinking May Keep Liver Cancer at Bay Aug 31, 2005
...put you at risk. Chronic hepatitis infection is one of those risk factors, as well as liver cirrhosis. While these conditions may ...
- Hepatitis Neighborhood
GlobeImmune Appoints Carl June, MD to Scientific Advisory Board Sep 1, 2005
The Company initiated a Phase 1b trial for its second product, GI-5005, a Tarmogen for the treatment of chronic hepatitis C infection in July 2005. ...
- dBusinessNews Denver (press release)
Emergent Biosolutions' Typhoid Vaccine Achieves Positive Results ... Aug 30, 2005
...company has already developed a vaccine against a common form of traveler's diarrhea (ETEC), and a therapeutic vaccine to treat chronic Hepatitis B carriers ...
- PR Newswire (press release)
This page is updated on a monthly basis if relevant articles are available. If you are looking for further information on
Chronic Hepatitis
you may want to try searching the Internet using the Google search box below.
|
|
|
